The business model is based on razors (the hand-held reusable controller) and razor blades (the disposable fiber optic). We are not manufacturing needles. The BrightPointTM Epidural device is used with existing FDA cleared needles & syringes (the clinicians do not need to change their current tools or work-flow to use the BrightPoint Epidural System). The hand-held controller has an estimated selling price of $1,000 and has a two-year warranty. The disposable, sterile fiber optic has an estimated selling price of $18 (per procedure). The device will be covered under current reimbursement codes for epidural accessories. 

There are currently no viable competitors in the Epidural Market. We are essentially creating a new segment in the medical device field with our platform technology (multi-spectral reflectometers for guiding needles and probes). Lumoptik recently received our first patent allowance. Any other company that tries to enter the epidural market with a similar "me too" product will violate our patent. We also have a letter of intent from the Hospital for Special Surgery (HSS) in New York. HSS is the number 1 orthopedic hospital in the US. The proposed collaboration agreement with HSS includes working together to create new Lumoptik platform products in the pain management and orthopedic markets as well as a $250K direct investment.

 : LUMOPTIK GO TO MARKET STRATEGY SUMMARY—this is dependent on how we develop a strategic relationship with a large commercial partner. During the FDA review period (while we are waiting) we will: • Publish results from the clinical trial at Univ Hosp in Cleveland right away on our website. o Extend the trial for a larger patient experience. • Start evaluation trials at 20 teaching hospitals and high-volume centers with Key Opinion Leaders (KOL’s). We have already spoken to: o University Hospital Cleveland o Cleveland clinic o Mount Sinai Hospital, NYC o Hospital for Special Surgery, NYC o University of MI o University of Wisconsin • The goal is to create a pipeline of published papers about the BrightPointTM Epidural System and set-up our first customers before we receive approval from the FDA • Once we have our clinical trial data--Contact distributors to set-up the supply chain prior to launch: o One pure national distributor (Medline, Henry Schein, etc.)